Abstract
Systematic studies on the oxygenation status of solid tumors have shown that the development of hypoxic/anoxic tissue subvolumes is a pathophysiological trait in a wide range of human malignancies. As a result of this characteristic property, adenosine (ADO) accumulation (range: 50-100 μM) occurs caused by intra- and extracellular generation of ADO. Extracellular nucleotide catabolism by hypoxia-/HIF-1α-sensitive, membrane-associated ecto-5'-nucleotidases most probably is the major source of ADO in the halo of cancer cells upon specific genetic alterations taking place during tumor growth. Extracellular ADO can act through autocrine and paracrine pathways following receptor-binding and involving different intracellular signalling cascades. Hypoxia-driven receptor activation can lead to a broad spectrum of strong immune-suppressive properties facilitating tumor escape from immune control (e.g., inhibition of CD4+, CD8+, NK and dendritic cells, stimulation of Treg cells). In addition, tumor growth and progression is promoted by ADO-driven direct stimulation of tumor cell proliferation, migration, invasion, metastatic dissemination, and an increase in the production of molecules stimulating tumor angiogenesis. Hypoxia- driven ADO ...Continue Reading
Citations
Mar 18, 2016·Cancer Immunology, Immunotherapy : CII·Jinbao ZongMichael R Shurin
Sep 16, 2016·Frontiers in Immunology·Peter Vaupel, Gabriele Multhoff
Apr 13, 2017·Expert Review of Anticancer Therapy·Theresa L Whiteside
Mar 5, 2017·Immunological Reviews·Bertrand AllardJohn Stagg
Dec 30, 2016·Molecules and Cells·Namgyu Lee, Dohoon Kim
Dec 23, 2016·Clinical Neurology and Neurosurgery·Chang Shu, Jinhuan Wang
Jan 10, 2018·Frontiers in Immunology·Peter Vaupel, Gabriele Multhoff
Feb 9, 2019·Advanced Healthcare Materials·Yuta AndoKeyue Shen
Jan 31, 2019·Stem Cells and Development·Luis Roberto Ávila-IbarraAlberto Monroy-García
Oct 21, 2016·Molecular Medicine·Alberto L HorensteinFabio Malavasi
Sep 4, 2016·Oncotarget·Claudia SorrentinoSilvana Morello
May 14, 2020·BMC Cancer·Hidenori TsukuiJoji Kitayama
Aug 31, 2019·Clinical and Translational Medicine·Babita Agrawal
Aug 11, 2020·The Journal of Cell Biology·Antoine A KhalilPeter Friedl
Oct 19, 2019·Cancers·Simone de LeveVerena Jendrossek
Dec 18, 2019·International Journal of Cancer. Journal International Du Cancer·Max WilkatCornelia Brunner
Jun 6, 2020·Purinergic Signalling·Marzia CarluccioRenata Ciccarelli
Aug 4, 2020·Science Advances·Rekha DhanwaniSonia Sharma
Jul 30, 2020·Cancers·Andriy ZhylkoAgnieszka Graczyk-Jarzynka
Mar 11, 2016·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Peter Vaupel, Gabriele Multhoff
Jan 26, 2020·Nature Communications·Miao YuYan Cui
Dec 17, 2020·Cancers·Arnulf MayerHeinz Schmidberger
Feb 17, 2021·International Immunopharmacology·Mohammad Hossein KazemiElahe Safari
Feb 22, 2021·Human Immunology·Alexey Churov, Galina Zhulai
May 28, 2021·World Journal of Gastrointestinal Oncology·Ross KingNoel E Donlon
Jul 1, 2021·Molecular Pharmaceutics·David A MurphyIsaac M Adjei
Jul 1, 2021·Cell Biology International·Keywan Mortezaee
Sep 21, 2021·Frontiers in Neuroscience·Alejandro Sánchez-MelgarMairena Martín